Skip to main content
NIH Record - 75th Anniversary - National Institutes of Health

NHLBI Seeks Adults with B-Cell Malignancies

NHLBI opens a new clinical trial testing the drug NX-2127 for adults with relapsed/refractory B-cell malignancies. NX-2127 is an oral drug that degrades a protein in B-cell malignancies, Bruton’s tyrosine kinase, instead of inhibiting or blocking it like other drugs. NX-2127 may also stimulate the body’s immune T-cells to attack cancer cells. The study enrolls adults 18 years or older diagnosed with a B-cell malignancy that progressed after prior systemic therapies. Participation is at no cost and travel assistance may be available. Contact the Office of Patient Recruitment at (866) 444-2214 (TTY users dial 711) or email: ccopr@nih.gov. Refer to study #000326-H. Online: https://go.usa.gov/xuPDr.

Have Psoriasis? CC Needs Volunteers

Do you or someone you know have mild to moderate psoriasis? Researchers at the Clinical Center are testing a form of vitamin B3 dietary supplement to help improve immune system function in the blood and skin of people with mild to moderate psoriasis. Treatments and research procedures are provided at no cost. Refer to study #20-H-0044. Online: https://go.usa.gov/xdH2Y. For more information, call the Office of Patient Recruitment at (866) 444-2214 (TTY users dial 711) or email ccopr@nih.gov.

Have Recurrent Prostate Cancer?

Join a clinical study looking to find a safer radiation treatment dosage. The standard treatment for recurrent prostate cancer after surgical removal of the prostate is radiation to the prostate bed delivered over 6-7 weeks. NCI’s Dr. Deborah Citrin is conducting a study to see whether a shortened or compressed radiation treatment schedule of 2, 3 or 4 weeks can be as effective as the standard. Contact the Office of Patient Recruitment at (866) 444-2214 (TTY users dial 711) or ccopr@nih.gov. Online: http://go.usa.gov/xtHdD. Refer to study #18-C-0028. 

Adults with Covid-19 Sought

NIMHD researchers are recruiting adults newly diagnosed with Covid-19 (within 72 hours) for a remote study. This is a remote study with no in-person visits. The study will collect physical health data using a temperature patch and digital wristband that will be provided to each patient. The collected data will be uploaded to an app using a smartphone and will help researchers gain a better understanding of how Covid-19 progresses in patients and its long-term effects in patient groups with different demographics and risk profiles. To learn more, contact the Office of Patient Recruitment at (866) 444-2214 (TTY users dial 711) or ccopr@nih.gov. Refer to study #000315. Online: https://go.usa.gov/x676m.

Back to Top